On July 24th, GLH - Fudan Zhangjiang (01349.HK) announced that the Phase I clinical trial of the injection FZ-AD005 antibody conjugate (anti-DLL3 antibody conjugate BB05) developed by the company for the treatment of advanced solid tumors has recently completed the enrollment of the first subject.
Clear
All
Quotes
News
Learn
Help
All
US
HK
CN
SG
AU
JP
All
News
Announcements
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
复旦张江(01349.HK):注射用FZ-AD005抗体偶联剂用于治疗晚期实体瘤I期临床试验完成首例受试者入组
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced completion of enrollment of the first participant in Phase I clinical trial of injectable FZ-AD005 antibody conjugate for the treatment of advanced solid tumors.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Like
Views 280
Write a comment
Statement
This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report